Mirum appoints Timothy Walbert to Board; Niall O'Donnell to resign at 2023 annual meeting

Mirum Pharmaceuticals, Inc.

Timothy Walbert appointed to Board as Class I director effective April 5, 2023.
Walbert receives option for 34,000 shares vesting over 3 years and $45,000 annual cash retainer.
Niall O'Donnell resigns as director and from Nominating and Corporate Governance Committee, effective at 2023 annual meeting, no dispute.
Walbert will serve until 2023 annual meeting and then be eligible for annual option grant of 17,000 shares.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Niall O'Donnell

Director

MIRM · Mirum Pharmaceuticals, Inc.

Filed: April 6, 2023, 7:59 PM ET

On April 5, 2023, Niall O’Donnell, Ph.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of his resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.

Appointed

Timothy Walbert

Director

MIRM · Mirum Pharmaceuticals, Inc.

Effective: 2023-04-05
Filed: April 6, 2023, 7:59 PM ET

On April 5, 2023, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Timothy Walbert to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Niall O'Donnell resigned as Director at Mirum Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 5, 2023, Niall O’Donnell, Ph.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of his resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy Walbert was appointed as Director at Mirum Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 5, 2023, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Timothy Walbert to the Board, effective immediately.

View on SEC.gov

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-093126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.